---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006716"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:57:31.820671+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioCryst and Clearside partner to develop avoralstat for DME via SCS Microinjector; $5M upfront

## Summary
- License agreement for avoralstat for diabetic macular edema using Clearside's SCS Microinjector.
- BioCryst pays $5M upfront; Clearside eligible for up to $30M in clinical/regulatory milestones and up to $47.5M in sales milestones.
- Avoralstat previously safe in Phase 3 HAE trial; high potency and low solubility suited for suprachoroidal delivery.
- DME is common cause of vision loss; one-third of patients don't respond to anti-VEGF therapies.
- BioCryst to host R&D Day today at 1:00 pm ET.

## SEC filing metadata
- accession: 0001171843-23-006716
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323006716/0001171843-23-006716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323006716/f8k_110323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006716
- JSON: https://secwatch.observer/filing/0001171843-23-006716.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.